Patent intelligence · US
US 8349848
Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
Patent details — US 8349848
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 8, 2013
- Expiration
- Jan 3, 2033
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Claims
- 18
- CPC classes
- A61P, A61P11/06, A61P11/08, A61P19/02
Quick answer
US 8349848 (Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Jan 8, 2013. Expires Jan 3, 2033 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P11/06, A61P11/08, A61P19/02, A61P3/00, A61P35/00
More from Dogwood Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9446021
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 9120754
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 8293720
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted -
US 8263762
Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
granted -
US 8258142
Substituted 8-[6-amino-3-pyridyl]xanthines
granted -
US 8252767
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted
Frequently asked questions
What is US patent 8349848?
US 8349848 (Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Jan 8, 2013. Expires Jan 3, 2033 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8349848?
Dogwood Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8349848 expire?
Our index shows an expiration date of Jan 3, 2033 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.